Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics

Drug Metabolism and Drug Interactions

Volumn 27, Issue 1, 2012, Pages 19-31

  Manolopoulos, Vangelis G ^a,b   Ragia, Georgia ^a   Alevizopoulos, Georgios ^c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Academic General Hospital Alexandroupolis   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

comorbidities; CYP450 enzymes; drug interactions; pharmacogenomics; pharmacokinetics; selective serotonin reuptake inhibitors

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ASTEMIZOLE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CODEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOPINAVIR; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; RITONAVIR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AKATHISIA; ANXIETY DISORDER; BIPOLAR DISORDER; BULIMIA; CHRONIC PAIN; COMORBIDITY; DEPRESSION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; EATING DISORDER; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME POLYMORPHISM; ENZYME SYNTHESIS; EPISTAXIS; GENERALIZED ANXIETY DISORDER; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HYPERSALIVATION; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PANIC; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; POLYPHARMACY; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PSYCHIATRIST; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SOMATOFORM DISORDER; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG TOXICITY; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; SMOKING;

EID: 84860508897     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2011-0033     Document Type: Review

References (180)

1. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009;15:1563-86.
2. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004;60:57-61. (Pubitemid 38471459)
3. Koenig AM, Thase ME. First-line pharmacotherapies for depression-what is the best choice? Pol Arch Med Wewn 2009;119:478-86.
4. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011;25:585-96.
5. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2011;71:839-54.
6. Capasso A, Petrella C, Milano W. Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders. Curr Clin Pharmacol 2009;4:78-83.
7. Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev 2009;1:CD005332.
8. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. Am J Health Syst Pharm 2011;68:1307-19.
9. Bastien DL. Pharmacological treatment of combat-induced PTSD: a literature review. Br J Nurs 2010;19:318-21.
10. Brown J, O'Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009;2:CD001396.
11. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011;9:90.
12. Lepine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011;7:3-7.
13. Walters P, Schofield P, Howard L, Ashworth M, Tylee A. The relationship between asthma and depression in primary care patients: a historical cohort and nested case control study. PLoS One 2011;6:e20750.
14. Nouwen A, Nefs G, Caramlau I, Connock M, Winkley K, Lloyd CE, et al. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care 2011;34: 752-62.
15. Wein S, Sulkes A, Stemmer S. The oncologist's role in managing depression, anxiety, and demoralization with advanced cancer. Cancer J 2010;16:493-9.
16. Cheatle MD. Depression, chronic pain, and suicide by overdose: on the edge. Pain Med 2011;12(Suppl 2):S43-8.
17. Korczyn AD, Halperin I. Depression and dementia. J Neurol Sci 2009;283:139-42.
18. Staner L. Comorbidity of insomnia and depression. Sleep Med Rev 2010;14:35-46.
19. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med 2007;45:801-14. (Pubitemid 47041905)
20. Vesell ES. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther 1977;22:659-79. (Pubitemid 8227787)
21. Vesell ES, Passananti GT. Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment. Environ Health Perspect 1977;20:159-82. (Pubitemid 8266919)
22. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011;63:437-59.
23. Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: cit-alopram pharmacokinetics pathway. Pharmacogenet Genomics 2011;21:769-72.
24. Pollock BG. Citalopram: a comprehensive review. Expert Opin Pharmacother 2001;2:681-98. (Pubitemid 32427761)
25. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010;11:537-46.
26. Aronson S, Delgado P. Escitalopram. Drugs Today (Barc) 2004;40:121-31. (Pubitemid 38387617)
27. LLerena A, Dorado P, Berecz R, Gonzalez AP, Penas LE. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norflu-oxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004;59:869-73. (Pubitemid 38337438)
28. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001;61:81-110. (Pubitemid 32108326)
29. Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001;57:653-8.
30. Brosen K. Some aspects of genetic polymorphism in the biotrans-formation of antidepressants. Therapie 2004;59:5-12. (Pubitemid 38765554)
31. Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000;61(Suppl 11):9-17. (Pubitemid 30616691)
32. Jornil J, Jensen KG, Larsen F, Linnet K. Identification of cytochrome P450 isoforms involved in the metabolism of par-oxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 2010;38:376-85.
33. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003;31:289-93. (Pubitemid 36249683)
34. Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother 2008;9:787-94. (Pubitemid 351566194)
35. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999;7:69-84. (Pubitemid 29426569)
36. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005;33:262-70. (Pubitemid 40216594)
37. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacoki-netics of sertraline. Clin Pharmacokinet 2002;41:1247-66.
38. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010;11:493-6.
39. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepi-genomic perspective. Pharmacogenomics 2011;12:1161-91.
40. Manolopoulos VG, Dechairo B, Huriez A, Kuhn A, Llerena A, van Schaik RH, et al. Pharmacogenomics and personalized medicine in clinical practice. Pharmacogenomics 2011;12:597-610.
41. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75-85. (Pubitemid 43017126)
42. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose mod-ifications of antidepressants. Clin Lab Med 2008;28:619-26.
43. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011;89: 662-73.
44. Jones DS, Perlis RH. Pharmacogenetics, race, and psychiatry: prospects and challenges. Harv Rev Psychiatry 2006;14:92-108.
45. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20:29-42. (Pubitemid 43061720)
46. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11.
47. Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol 2010;70:749-55.
48. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15-9. (Pubitemid 38869995)
49. Shah RR. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules. Expert Opin Drug Saf 2005;4:103-28.
50. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7:165-82.
51. Roy K, Roy PP. QSAR of cytochrome inhibitors. Expert Opin Drug Metab Toxicol 2009;5:1245-66.
52. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 2001;18:1071-80. (Pubitemid 32900389)
53. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22. (Pubitemid 46051438)
54. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacoki-netic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27.
55. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertra-line. J Clin Psychopharmacol 1997;17:102-6. (Pubitemid 27148305)
56. von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today (Barc) 2007;43:221-47. (Pubitemid 47177209)
57. Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J Clin Psychopharmacol 2002;22:326-9. (Pubitemid 34546849)
58. Jana S, Paliwal J. Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions. Curr Protein Pept Sci 2007;8:619-28. (Pubitemid 351266993)
59. Carroccio A, Wu D, Cederbaum AI. Ethanol increases content and activity of human cytochrome P4502E1 in a transduced HepG2 cell line. Biochem Biophys Res Commun 1994;203:727-33. (Pubitemid 24281154)
60. Kroon LA. Drug interactions and smoking: raising awareness for acute and critical care providers. Crit Care Nurs Clin North Am 2006;18:53-62, xii. (Pubitemid 43402630)
61. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
62. Aranow AB, Hudson JI, Pope HG Jr, Grady TA, Laage TA, Bell IR, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989;146:911-3. (Pubitemid 19180974)
63. Vandel S, Bertschy G, Bonin B, Nezelof S, Francois TH, Vandel B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992;25:202-7.
64. Muller N, Brockmoller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele-a slowly reversible interaction with fluoxetine. Ther Drug Monit 1991;13:533-6.
65. Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur J Clin Pharmacol 1993;44: 403-5. (Pubitemid 23153464)
66. Diaz FJ, Santoro V, Spina E, Cogollo M, Rivera TE, Botts S, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008;41:81-91. (Pubitemid 351796981)
67. Joos AA, Konig F, Frank UG, Kaschka WP, Morike KE, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry 1997;30:266-70. (Pubitemid 28006080)
68. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007;9:618-27. (Pubitemid 47365630)
69. Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004;55:1103-9. (Pubitemid 38680563)
70. Nelson LA, Swartz CM. Melancholic symptoms during concurrent olanzapine and fluoxetine. Ann Clin Psychiatry 2000;12:167-70.
71. Hori T, Makabe K, Nemoto K, Asada T. Hypersalivation induced by olanzapine with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:758-60.
72. Saito M, Yasui-Furukori N, Nakagami T, Furukori H, Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005;25:527-32. (Pubitemid 41669043)
73. Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005;33:845-52. (Pubitemid 40686639)
74. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacoki-netic drug interaction. J Clin Psychopharmacol 2002;22:419-23. (Pubitemid 34810333)
75. Mowla A, Dastgheib SA, Ebrahimi AA, Pani A. Nasal bleeding associated with fluoxetine and risperidone interaction: a case report. Pharmacopsychiatry 2009;42:204-5.
76. Kopala LC, Day C, Dillman B, Gardner D. A case of risperidone overdose in early schizophrenia: a review of potential complications. J Psychiatry Neurosci 1998;23:305-8. (Pubitemid 29022209)
77. Fukui H, Murai T. Severe weight gain induced by combination treatment with risperidone and paroxetine. Clin Neuropharmacol 2002;25:269-71. (Pubitemid 35239486)
78. Llerena A, Kiivet RA. Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use. Br J Clin Pharmacol 1994;37:531-2. (Pubitemid 24197144)
79. Lucena MI, Blanco E, Corrales MA, Berthier ML. Interaction of fluoxetine and valproic acid. Am J Psychiatry 1998;155:575.
80. Sovner R, Davis JM. A potential drug interaction between flu-oxetine and valproic acid. J Clin Psychopharmacol 1991;11:389.
81. Cruz-Flores S, Hayat GR, Mirza W. Valproic toxicity with fluox-etine therapy. Mo Med 1995;92:296-7.
82. Fritze J, Unsorg B, Lanczik M. Interaction between carbam-azepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-4.
83. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 1993;36:615-6. (Pubitemid 24001728)
84. Kasper S, Resinger E. Panic disorder: the place of benzo-diazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 2001;11:307-21. (Pubitemid 32781011)
85. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepres-sants. J Clin Psychopharmacol 1995;15:125-31.
86. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake- inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31. (Pubitemid 24222832)
87. Hall J, Naranjo CA, Sproule BA, Herrmann N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazo-lam by citalopram and fluoxetine. J Clin Psychopharmacol 2003;23:349-57. (Pubitemid 36951176)
88. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clon-azepam. Clin Pharmacol Ther 1992;52:479-86.
89. Pazzagli L, Banfi R, Borselli G, Semmola M V. Photosensitivity reaction to fluoxetine and alprazolam. Pharm World Sci 1998;20:136. (Pubitemid 28204309)
90. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991;104:323-7.
91. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6. (Pubitemid 24370353)
92. Suzuki Y, Kawashima Y, Shioiri T, Someya T. Effects of concomitant fluvoxamine on the plasma concentration of etizolam in Japanese psychiatric patients: wide interindividual variation in the drug interaction. Ther Drug Monit 2004;26:638-42. (Pubitemid 39579145)
93. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of flu-oxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1 ′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995;275:1131-5. (Pubitemid 26130628)
94. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91. (Pubitemid 26329500)
95. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011;12:496-503.
96. Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009;55:1770-82.
97. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
98. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J Am Med Assoc 2009;302:1429-36.
99. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74. (Pubitemid 43946844)
100. Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011;29:3232-9.
101. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 2008;30:112-26. (Pubitemid 351248974)
102. Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas 2010;67:296-308.
103. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J 2010;340:c693.
104. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010;28:2768-76.
105. Reaume KT, Regal RE, Dorsch MP. Indications for dual anti-platelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother 2008;42:550-7. (Pubitemid 351522787)
106. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251-9.
107. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597-602. (Pubitemid 41716544)
108. Fernando H, Dart AM, Peter K, Shaw JA. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 2011;105:933-44.
109. Clopidogrel Bisulfate (marketed as Plavix)-Prescribing and Label Information. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/ 2011/020839s051lbl.pdf. Accessed 5 September, 2011.
110. Huffman JC, Mastromauro CA, Sowden G, Fricchione GL, Healy BC, Januzzi JL. Impact of a depression care management program for hospitalized cardiac patients. Circ Cardiovasc Qual Outcomes 2011;4:198-205.
111. Mazza M, Lotrionte M, Biondi-Zoccai G, Abbate A, Sheiban I, Romagnoli E. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol 2010;24:1785-92.
112. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37. (Pubitemid 34296308)
113. Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007;120:188-92. (Pubitemid 47042251)
114. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006;119:113-6. (Pubitemid 43151473)
115. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Anti Depressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108: 939-44. (Pubitemid 37048222)
116. Balhara YP, Sagar R. Correlates of anxiety and depression among patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 2011;15:S50-4.
117. Roy T, Lloyd CE, Pouwer F, Holt RI, Sartorius N. Screening tools used for measuring depression among people with type 1 and type 2 diabetes: a systematic review. Diabet Med 2012;29:164-75.
118. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001;13:31-41. (Pubitemid 32660581)
119. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypogly-cemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009;10:1781-7.
120. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997;32(Suppl 1): 31-6. (Pubitemid 27107717)
121. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001;69:41-7. (Pubitemid 32108670)
122. Tirkkonen T, Heikkila P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphony-lureas glibenclamide, glimepiride or glipizide. J Intern Med 2010;268:359-66.
123. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
124. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, et al. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001;70:415-24. (Pubitemid 33135320)
125. Rasmussen BB, Jeppesen U, Gaist D, Brosen K. Griseofulvin and fluvoxamine interactions with the metabolism of theophyl-line. Ther Drug Monit 1997;19:56-62. (Pubitemid 28068996)
126. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991;6:460-2.
127. Sayal KS, Duncan-McConnell DA, McConnell HW, Taylor DM. Psychotropic interactions with warfarin. Acta Psychiatr Scand 2000;102:250-5.
128. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996;16:273-85. (Pubitemid 26254878)
129. Teichert M, Visser LE, Uitterlinden AG, Hofman A, Buhre PJ, Straus S, et al. Selective serotonin reuptake inhibiting antidepres-sants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol 2011;72:798-805.
130. Limke KK, Shelton AR, Elliott ES. Fluvoxamine interaction with warfarin. Ann Pharmacother 2002;36:1890-2. (Pubitemid 35429561)
131. Yap KB, Low ST. Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Med J 1999;40:480-2. (Pubitemid 29376898)
132. Claire RJ, Servis ME, Cram DL Jr. Potential interaction between warfarin sodium and fluoxetine. Am J Psychiatry 1991;148:1604.
133. Woolfrey S, Gammack NS, Dewar MS, Brown PJ. Fluoxetine-warfarin interaction. Br Med J 1993;307:241. (Pubitemid 23207906)
134. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997;17:170-2. (Pubitemid 27057132)
135. Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010;10:85-93.
136. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 2011;87:274-85.
137. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105:231-8. (Pubitemid 37162492)
138. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004;43: 983-1013. (Pubitemid 39602014)
139. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-65. (Pubitemid 47202488)
140. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinet-ics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008;28:78-83.
141. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31. (Pubitemid 40051906)
142. Reus VI, Rawitscher L. Possible interaction of tramadol and an-tidepressants. Am J Psychiatry 2000;157:839.
143. John AP, Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. Aust N Z J Psychiatry 2007;41:192-3.
144. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. Int J Geriatr Psychiatry 1998;13:343-5. (Pubitemid 28254585)
145. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int Clin Psychopharmacol 1997;12:181-2. (Pubitemid 27283328)
146. Devulder J, De Laat M, Dumoulin K, Renson A, Rolly G. Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Acta Clin Belg 1996;51:184-6. (Pubitemid 26239544)
147. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. J Clin Psychopharmacol 2002;22:440-1. (Pubitemid 34810341)
148. Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA. Mania and tramadol-fluoxetine combination. Am J Psychiatry 2001;158:964-5.
149. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med 1999;92:474-5. (Pubitemid 29457148)
150. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxy-codone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461-79.
151. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxy-codone. Br J Pharmacol 2010;160:907-18.
152. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxy-codone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig 2011;31:143-53.
153. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol 2010;160:919-30.
154. Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krahenbuhl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2011;67:63-71.
155. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol 2010;70:78-87.
156. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66:814-22. (Pubitemid 39552863)
157. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 2003;54:241-7. (Pubitemid 37267854)
158. van Melle JP, Verbeek DE, van den Berg MP, Ormel J, van der Linde MR, de Jonge P. Beta-blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll Cardiol 2006;48:2209-14. (Pubitemid 44855428)
159. Wade AG. Antidepressants in panic disorder. Int Clin Psychopharmacol 1999;14(Suppl 2):S13-7. (Pubitemid 29358975)
160. Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009;85:269-72.
161. Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 2009;85:45-50.
162. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J, et al. Increased frequency of cytochrome P450 2D6 poor metaboliz-ers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002;72:429-37. (Pubitemid 35178868)
163. Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, et al. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol 2011;51:389-96.
164. Hemeryck A, De Vriendt CA, Belpaire FM. Metoprolol-paroxetine interaction in human liver microsomes: stereose-lective aspects and prediction of the in vivo interaction. Drug Metab Dispos 2001;29:656-63. (Pubitemid 32374566)
165. Stout SM, Nielsen J, Bleske BE, Shea M, Brook R, Kerber K, et al. The impact of paroxetine coadministration on stereospe-cific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther 2010;15:373-9.
166. Gruwez B, Dauphin A, Tod M. A mathematical model for par-oxetine antidepressant effect time course and its interaction with pindolol. J Pharmacokinet Pharmacodyn 2005;32:663-83. (Pubitemid 41772352)
167. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002;22:211-5. (Pubitemid 34289398)
168. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001;31:1-10. (Pubitemid 32337057)
169. Priskorn M, Larsen F, Segonzac A, Moulin M. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol 1997;52:241-2. (Pubitemid 27278382)
170. Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18: 111-7. (Pubitemid 26104615)
171. Levin TT, Cortes-Ladino A, Weiss M, Palomba ML. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. Gen Hosp Psychiatry 2008;30:372-7. (Pubitemid 351862318)
172. Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999;19: 894-6. (Pubitemid 29415848)
173. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43(Suppl 2):37-44. (Pubitemid 34229485)
174. Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 2000;61:526-7. (Pubitemid 30483425)
175. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur J Clin Pharmacol 2002;57:915-6. (Pubitemid 34185565)
176. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
177. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001;15:469-94. (Pubitemid 32601905)
178. Sugahara H, Maebara C, Ohtani H, Handa M, Ando K, Mine K, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol 2009;65: 699-704.
179. Katoh Y, Uchida S, Kawai M, Takei N, Mori N, Kawakami J, et al. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull 2010;33:285-8.
180. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Inoue Y, et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 2011;25:908-14.